Group items tagged

The overall goal of this FOA is to support the development of a collaborative research and resource network to synergize the expertise, skills, and resources of investigators within the geriatric emergency medicine and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) research communities to identify and address research gaps towards optimizing recognition and emergency care of older adults with AD/ADRD.

The Saucony Run For Good Foundation is committed to improving the lives of children by helping to prevent and reduce childhood obesity. According to the foundation, today's American youth are considered the most inactive in history and as a result the rate of obesity among U.S. children and teenagers has more than tripled over the past three decades. To that end, Saucony is inviting proposals aimed at helping run down the childhood obesity epidemic. Grants of up to $10,000 will be awarded to community-based nonprofit organizations that initiate and support running programs for kids. Program participants must be 18 years of age or younger, and the foundation will prioritize programs that serve populations not traditionally exposed to running programs.

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support two types of cancer centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas. The purpose of both types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious programs in laboratory, clinical, and population research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of shared resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

The FY19 GWIRP Clinical Evaluation Award supports translation of validated GWI research, including qualified and replicated preclinical findings, to a Gulf War Veteran population. The Clinical Evaluation Award targets the Verification phase of the research pipeline as outlined in Section II.A.2. Statistically powered biomarker trials with the potential to validate use of biomarkers as clinical endpoints or proof-of-concept intervention trials (e.g., pilot, first in human, Phase I-IIa) are encouraged under this funding opportunity. While studies of treatments repurposed from other disorders sharing GWI symptomatology will be considered (with appropriate rationale), the FY19 GWIRP encourages studies that translate qualified results from the GWI research community.

The intent of the FY19 PRARP InCASA is to support innovative research that improves the quality of life and care for individuals living with the common symptoms of TBI and/or AD/ADRD and/or their families and care providers, as related to the PRARP's mission (see Section II.A, Program Description). The proposed work should innovatively challenge existing research paradigms or exhibit high levels of creativity within the contexts of the PRARP's mission and vision. This can include innovations and research for symptom reduction (e.g., cognitive, behavioral, function, mood), resiliency factors, increasing or maintaining independence, and support for families and care providers. The research innovations for the FY19 PRARP InCASA are expected to benefit the military, Veteran, and civilian communities. FY19 PRARP InCASA applications should be Innovation- and Impact-based.

The intent of this announcement is to partner with national organizations that have a demonstrated reach and influence in one or more of the following targeted populations; the African American/Black, Hispanics/Latino, Gay, Bisexual Men Who Have Sex With Men (MSM), and Transgender population in order to assist DHAP in HIV/AIDS Prevention.

Nicotine is a substance that occurs naturally in tobacco leaves. American Blend cigarettes use three different types of tobacco ranging in nicotine content:  (1) Flue-cured tobacco with leaf ranging from 15 to 45 mg/g and stem from 3 to 7 mg/g, (2) Burley tobacco with leaf ranging from 15 to 50 mg/g and stem from 3 to 7 mg/g, and (3) Oriental tobacco with leaf ranging from 5 to 20 mg/g (this type is not stemmed).  Given these ranges and common blending approaches, the nicotine content in most American Blend cigarettes ranges from 14 to 27 mg/g. There exists the possibility that future governmental regulations will require a significant reduction in the concentration of nicotine in tobacco products. Existing extraction technologies can reduce the amount of nicotine by 90% but are very expensive, or they eliminate the sensorial characteristics and flavor compounds of tobacco as well. NineSigma's client desires a cost-effective technology to significantly lower levels of nicotine in tobacco leaves by 50% or more.

NineSigma, representing a multi-billion-dollar medical instruments manufacturer, is looking for development partners to realize next-generation balloon catheters. The main development object involves balloon parts that act as components for balloon catheters. The client seeks technology that resolves the challenges of pressure resistance, flexibility, etc., and that is applicable to the field of medical instruments. The client also widely welcomes materials, structural designs, manufacturing methods, etc., that are used in other fields.

GSK Consumer Healthcare currently is the largest global marketer of nicotine replacement therapies (NRT) for smoking cessation. We serve patients in over 20 countries, including the US, Canada, across Europe, and Australia. GSK Consumer Healthcare strives to transform the future of self-care. We hope to leverage the wisdom of experts within the fields of nicotine and tobacco research to identify areas of critical and emerging unmet needs within the tobacco cessation and reduction space and collaborate with key scientific partners to help deliver upon them.

NineSigma, on behalf of Prapela, Inc., seeks organizations interested in collaborating to conduct clinical studies for assessment and regulatory clearance of a non-pharmacological treatment for newborns diagnosed with neonatal abstinence syndrome. NineSigma invites interested Ohio-based candidates to promptly submit a brief, non-confidential statement of interest.

NineSigma, representing Sumitomo Dainippon Pharma Co., Ltd. (https://www.ds-pharma.com/) ("Client"), seeks a drug modality for novel anti-cancer drugs that target immunosuppressive cells and interfere with immune functions, or an evaluation system for creating a drug modality. In recent years, the emergence of immune checkpoint inhibitors has been gradually revealing that the local immunosuppressive environment in tumor affects cancer treatment. This attracts interest in the development of novel antitumor drugs for improving the immune state of the tumor microenvironment. In particular, we look for compounds that target host cells contributing to the formation of the immunosuppressive environment and interfering with these functions.

NineSigma, representing a major food manufacturer, seeks a technology of in vivo fluorescence labeling of any protein or mRNA using antibodies/probes. Specifically, the client anticipates proposals for technologies such as: Technology to design/produce fluorescence-labeled detection probes (antibodies, low molecular weight probes, etc.) Technology to easily introduce the fluorescence-labeled detection probe into living cells in a highly efficient manner

Through the program, one-year grants of up to $40,000 will be awarded to projects that investigate various aspects of hearing and balance disorders related to the inner ear. Priority will be given to investigators early in their careers who need seed funds to generate results and data that can be used to support applications for larger grants (i.e., NIH grants) in the future. Projects should relate to the hearing or balance functions of the ear. Both basic and clinical studies that investigate aspects of the auditory and vestibular systems, including but not limited to genetics, neurotology, anatomy, auditory processing, molecular and cellular biology, therapeutic studies, and investigations of current or experimental devices (i.e., cochlear implants), may be proposed. Funding may only be used for direct costs, including salaries of technical and supporting staff, equipment related to the research, and supplies. The grants will not support the salary of the principal investigator, travel or conference attendance, or educational costs.

The Sun Life Team Up Against Diabetes grant program is dedicated to addressing the prevention of diabetes and its related complications. Grants are provided to nonprofit organizations throughout the country that focus on the following areas: diabetes prevention, awareness, education, and care; diabetes management; recovery and support from diabetes-related complications; obesity prevention; and nutritional programs, including education, management, and awareness. Grants of $25,000, $50,000, or $100,000 are provided. The application deadline is March 31, 2018. Visit the Sun Life website to submit an online application.